Guardant Health Reveals Preliminary 2024 Results
Guardant Health, Inc. (NASDAQ: GH), a leader in precision oncology, has recently shared its preliminary and unaudited financial results for the full year and fourth quarter ending December 31, 2024. This announcement shines a light on the company’s growth trajectory in the oncology sector.
Highlights from Q4 2024
During the fourth quarter of 2024, Guardant Health saw impressive growth compared to the same period in 2023:
- Total revenue reached approximately $200 million, reflecting a remarkable increase of 29% from the previous year.
- The company reported around 57,300 oncology clinical tests, excluding Shield, and approximately 11,050 biopharma tests. This represents increases of 24% and 16%, respectively.
- In terms of Shield screening tests, Guardant Health reported approximately 6,400 tests completed, contributing about $4 million to the company’s revenue.
Overview of Full Year 2024 Performance
For the entire year ending December 31, 2024, Guardant Health's performance continued to impress:
- Total revenue for the year was approximately $737 million, marking a 31% increase compared to 2023.
- Guardant Health performed around 206,700 oncology clinical tests, excluding Shield, alongside approximately 40,500 biopharma tests. This demonstrates increases of 20% and 35%, respectively.
Financial Overview and Cash Flow
Despite the evident revenue growth, the company faced challenges with its cash flow. Guardant Health reported a preliminary unaudited free cash flow of approximately negative $84 million for the fourth quarter of 2024, accumulating to about negative $275 million for the entire year. However, the company maintained a solid financial position with cash, cash equivalents, restricted cash, and marketable debt securities totaling $944 million as of December 31, 2024.
Strategic Insights from Leadership
Co-founder and co-CEO Helmy Eltoukhy expressed excitement about the year’s achievements: “2024 was an outstanding year for Guardant. We delivered key milestones across the portfolio and completed the upgrade of Guardant360 LDT onto our Smart Liquid Biopsy platform. We finished the year strong with preliminary full-year revenue growth of 31%, driven by strong clinical and biopharma revenue and increasing Guardant360 ASPs.”
Future growth opportunities
Co-founder and co-CEO AmirAli Talasaz noted the successful launch of Shield and the significant opportunity for growth in commercial infrastructure: “We are extremely pleased with the strong traction and support we saw in the first full quarter of commercial launch of Shield. Given this success, we are focused on rapidly growing our commercial infrastructure to capture the massive opportunity ahead.”
Looking Ahead
Guardant Health is currently in the midst of preparing its audited financial statements for the fourth quarter and full year of 2024. These preliminary numbers are subject to change as the company completes its customary year-end procedures. The finalized results will be reported during Guardant's February earnings call in 2025.
About Guardant Health
Founded in 2012, Guardant Health is at the forefront of precision oncology, dedicated to improving patient outcomes and accelerating cancer therapies. The company utilizes advanced blood and tissue tests, along with AI analytics, to provide essential insights into the complexities of cancer. Its innovative tests serve to enhance care across all stages, from early detection to treatment selection for advanced cancer patients.
Frequently Asked Questions
What are the key financial highlights for Guardant Health in 2024?
Guardant Health reported a total revenue of approximately $737 million for 2024, showcasing a 31% growth compared to 2023.
How did Guardant Health perform in the fourth quarter?
The fourth quarter saw total revenue of about $200 million, marking a 29% increase over the same quarter in the previous year.
What challenges did Guardant Health face in 2024?
While experiencing significant revenue growth, the company reported negative free cash flow of approximately $84 million in Q4 2024.
When will Guardant Health publish its audited results?
The audited financial results for the fourth quarter and full year of 2024 will be reported during the February 2025 earnings call.
What is Guardant Health's mission?
Guardant Health aims to protect wellness by providing innovative solutions that enhance patient care through precision oncology.
